CC趋化因子配体调控胃癌的研究现状及进展

doi:10.3969/j.issn.1004-583X.2026.04.012

摘要/Abstract

摘要：

胃癌(gastric cancer,GC)是全球范围内发病率和病死率均较高的恶性肿瘤之一,多数患者确诊时已达中晚期。CC趋化因子配体(C-C motif chemokine ligand,CCL)是重塑GC肿瘤微环境及驱动恶性进展的核心分子。研究证实,CCL在GC中通过构建免疫抑制微环境,增强GC细胞的增殖、侵袭、转移能力及上皮-间质转化过程等多重机制,从而推动GC的发生和发展,与侵袭转移及预后密切相关。本文就CCL家族中代表性成员调控胃癌的研究现状及进展进行综述,以梳理靶向CCL的GC治疗潜力。

关键词: 胃肿瘤, CC趋化因子配体, 肿瘤微环境, 上皮间质转化, 靶向治疗

中图分类号:

R735.2

李鑫月, 李世豪, 刘娜, 吴婧, 李美玲, 刘改芳. CC趋化因子配体调控胃癌的研究现状及进展[J]. 临床荟萃, 2026, 41(4): 363-368.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.04.012

https://www.lchc.cn/CN/Y2026/V41/I4/363

参考文献 46

[1]	Sundar R, Nakayama I, Markar SR, et al. Gastric cancer[J]. Lancet, 2025, 405(10494):2087-2102. doi: 10.1016/S0140-6736(25)00052-2. pmid: 40319897
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231. doi: 10.3760/cma.j.cn112152-20240119-00035.
[3]	Lee CK, Jeong SH, Jang C, et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation[J]. Science, 2019, 363(6427):644-649. doi: 10.1126/science.aav0173.
[4]	Tian Y, Xie Y, Yi G, et al. Prognostic value and therapeutic significance of CCL chemokines in gastric cancer[J]. Curr Med Chem, 2024, 31(42):7043-7058. doi: 10.2174/0109298673315146240731100101. pmid: 39129286
[5]	Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer[J]. Immunity, 2021, 54(5):859-874. doi: 10.1016/j.immuni.2021.01.012. pmid: 33838745
[6]	Korbecki J, Kojder K, Simińska D, et al. CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4[J]. Int J Mol Sci, 2020, 21(21):8412. doi: 10.3390/ijms21218412.
[7]	Wu J, Liu X, Wang Y. Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer[J]. BMC Clin Pathol, 2013, 13:15. doi: 10.1186/1472-6890-13-15. pmid: 23697837
[8]	Liu H, Shen Z, Wang X, et al. Increased expression of C-C motif ligand 2 associates with poor prognosis in patients with gastric cancer after gastrectomy[J]. Tumour Biol, 2016, 37(3):3285-3293. doi: 10.1007/s13277-015-4092-9.
[9]	Zhang J, Yan Y, Cui X, et al. CCL2 expression correlates with Snail expression and affects the prognosis of patients with gastric cancer[J]. Pathol Res Pract, 2017, 213(3):217-221. doi: 10.1016/j.prp.2016.12.013. pmid: 28215642
[10]	Tao LL, Shi SJ, Chen LB, et al. Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia[J]. World J Gastroenterol, 2014, 20(15):4421-4427. doi: 10.3748/wjg.v20.i15.4421.
[11]	Zhao Z, Sun H, Liu Y, et al. PDPN+ cancer-associated fibroblasts enhance gastric cancer angiogenesis via AKT/NF-κB activation and the CCL2-ACKR1 axis[J]. MedComm (2020), 2025, 6(1):e70037. doi: 10.1002/mco2.70037.
[12]	Yan J, Gao Y, Lin S, et al. EGR1-CCL2 feedback loop maintains epithelial-mesenchymal transition of cisplatin-resistant gastric cancer cells and promotes tumor angiogenesis[J]. Dig Dis Sci, 2022, 67(8):3702-3713. doi: 10.1007/s10620-021-07250-5.
[13]	Statement of retraction: Long non-coding RNA CCL2 promoted gastric cancer function via miR-128/ PARP2 signal pathway[J]. Bioengineered, 2024, 15(1):2299621. doi: 10.1080/21655979.2024.2299621.
[14]	Cui Y, Chang Y, Ma X, et al. Ephrin A1 stimulates CCL2 secretion to facilitate premetastatic niche formation and promote gastric cancer liver metastasis[J]. Cancer Res, 2025, 85(2):263-276. doi: 10.1158/0008-5472.CAN-24-1254.
[15]	Zhang Y, Fan B, Yang H, et al. CCL2/CCR2 signaling pathway in tumorigenesis and metastasis (review)[J]. Oncol Lett, 2025, 30(6):598. doi: 10.3892/ol.2025.15344.
[16]	Lee SH, Lee D, Choi J, et al. Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages[J]. Gut, 2025, 74(5):714-727. doi: 10.1136/gutjnl-2024-332901.
[17]	Liu K, Yuan S, Wang C, et al. Resistance to immune checkpoint inhibitors in gastric cancer[J]. Front Pharmacol, 2023, 14:1285343. doi: 10.3389/fphar.2023.1285343.
[18]	Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression[J]. Mediators Inflamm, 2014, 2014:292376. doi: 10.1155/2014/292376.
[19]	Kim J, Kim JW, Kim Y, et al. Differential association of RANTES-403 and IL-1B-1464 polymorphisms on histological subtypes in male Korean patients with gastric cancer[J]. Tumour Biol, 2014, 35(4):3765-3770. doi: 10.1007/s13277-013-1498-0.
[20]	Yan YJ, Liu X, Wang D, et al. Tumor-Derived EBI3 Promotes CD8+ T-cell Exhaustion via STAT4-IL10/CCL5 in Gastric Cancer[J]. Cancer Immunol Res, 2025, 13(11):1873-1886. doi: 10.1158/2326-6066.CIR-24-1228.
[21]	Ding H, Zhao L, Dai S, et al. CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer[J]. Biomed Pharmacother, 2016, 77:142-149. doi: 10.1016/j.biopha.2015.12.004. pmid: 26796278
[22]	Wu Z, Qu B, Yuan M, et al. CRIP1 reshapes the gastric cancer microenvironment to facilitate development of lymphatic metastasis[J]. Adv Sci (Weinh), 2023, 10(26):e2303246. doi: 10.1002/advs.202303246.
[23]	Okamoto D, Yamauchi N, Takiguchi G, et al. Autonomous and intercellular chemokine signaling elicited from mesenchymal stem cells regulates migration of undifferentiated gastric cancer cells[J]. Genes Cells, 2022, 27(5):368-375. doi: 10.1111/gtc.12933.
[24]	Song S, He X, Wang J, et al. A novel long noncoding RNA, TMEM92-AS1, promotes gastric cancer progression by binding to YBX1 to mediate CCL5[J]. Mol Oncol, 2021, 15(4):1256-1273. doi: 10.1002/1878-0261.12863. pmid: 33247987
[25]	Wang T, Wei Y, Tian L, et al. C-C motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis[J]. Int J Surg, 2016, 32:136-142. doi: 10.1016/j.ijsu.2016.07.008. pmid: 27398691
[26]	Yang T, Chen M, Yang X, et al. Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5/CCR5 axis[J]. Cancer Biol Ther, 2017, 18(10):806-815. doi: 10.1080/15384047.2017.1373219. pmid: 28934010
[27]	孙立伶, 陆文奇. 血清趋化因子配体18在胃癌及癌前病变中的表达意义[J]. 现代医药卫生, 2011, 27(2):170-171.
[28]	Huang H, Li J, Hu WJ, et al. Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis[J]. J BUON, 2018, 23(4):1185-1194. pmid: 30358230
[29]	Hou X, Zhang Y, Qiao H. CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-κB signaling pathway[J]. Tumour Biol, 2016, 37(1):641-651. doi: 10.1007/s13277-015-3825-0.
[30]	Liu J, Li SM. MiR-484 suppressed proliferation, migration, invasion and induced apoptosis of gastric cancer via targeting CCL-18[J]. Int J Exp Pathol, 2020, 101(6):203-214. doi: 10.1111/iep.12366.
[31]	陈伟, 张靖, 朱金水. CCL20及其受体CCR6与消化系肿瘤[J]. 现代肿瘤医学, 2018, 26(24):4032-4035.
[32]	缪孟郡, 方志红, 程菁祎. 胃癌患者血清趋化因子L20、热休克蛋白70的表达及意义[J]. 医学临床研究, 2019, 36(12):2346-2348. doi: 10.3969/j.issn.1671-7171.2019.12.019.
[33]	Liu Y, Wei D, Deguchi Y, et al. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment[J]. Gastric Cancer, 2023, 26(6):904-917. doi: 10.1007/s10120-023-01418-w. pmid: 37572185
[34]	靳玉红, 宋世义, 范颖英, 等. 伴Hp感染胃癌前病变血清PGⅠ/PGⅡ、sHLA-G、CCL20水平及与胃癌转化的关系[J]. 中华医院感染学杂志, 2024, 34(14):2168-2172. doi: 10.11816/cn.ni.2024-231727.
[35]	Hwang TL, Lee LY, Wang CC, et al. CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis[J]. World J Gastroenterol, 2012, 18(11):1249-1256. doi: 10.3748/wjg.v18.i11.1249.
[36]	Yang S, Dong D, Bao X, et al. CCL21 and CLDN11 are key driving factors of lymph node metastasis in gastric cancer[J]. Cancer Control, 2024, 31:10732748241238616. doi: 10.1177/10732748241238616.
[37]	Fu Q, Tan X, Tang H, et al. CCL21 activation of the MALAT1/SRSF1/mTOR axis underpins the development of gastric carcinoma[J]. J Transl Med, 2021, 19(1):210. doi: 10.1186/s12967-021-02806-5. pmid: 34001131
[38]	Tang F, Chen JN, Zhang NN, et al. Expression of CCL21 by EBV-associated gastric carcinoma cells protects CD8+CCR7+ T lymphocytes from apoptosis via the mitochondria-mediated pathway[J]. Pathology, 2018, 50(6):613-621. doi: 10.1016/j.pathol.2018.05.004.
[39]	鲁佗. 胃癌患者血清CC趋化因子配体22表达与临床特征及预后关系的研究[J]. 中国药物与临床, 2022, 22(7):649-652.
[40]	Wei Y, Wang T, Song H, et al. C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy[J]. J Surg Res, 2017, 211:266-278. doi: 10.1016/j.jss.2016.11.067. pmid: 28501127
[41]	Wang G, Yu D, Tan W, et al. Genetic polymorphism in chemokine CCL22 and susceptibility to Helicobacter pylori infection-related gastric carcinoma[J]. Cancer, 2009, 115(11):2430-2437. doi: 10.1002/cncr.24255.
[42]	Chavez B, Kiaris H. Insights on the role of the chemokine CCL8 in pathology[J]. Cell Signal, 2025, 134:111951. doi: 10.1016/j.cellsig.2025.111951.
[43]	王晓娟, 董娜, 刘世琼. GKN2、CCL17表达与胃癌病理分期及预后的关系[J]. 实用癌症杂志, 2022, 37(5):716-719+723.
[44]	Xu D, Liu X, Ke S, et al. CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer[J]. BMC Cancer, 2023, 23(1):464. doi: 10.1186/s12885-023-10882-7. pmid: 37208608
[45]	Yu H, Mei Y, Dong Y, et al. CCR9-CCL25 mediated plasmacytoid dendritic cell homing and contributed the immunosuppressive microenvironment in gastric cancer[J]. Transl Oncol, 2023, 33:101682. doi: 10.1016/j.tranon.2023.101682.
[46]	Ji L, Qian W, Gui L, et al. Blockade of β-catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration[J]. Cancer Res, 2020, 80(10):2004-2016. doi: 10.1158/0008-5472.CAN-19-3074. pmid: 32156780

CC趋化因子配体调控胃癌的研究现状及进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 46

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈文江, 舒展, 周来显. 基于核酸适配体的肺癌诊断和治疗研究进展[J]. 临床荟萃, 2025, 40(8): 742-747.
[2]	范玉雯, 宋佳, 黄盼娜, 张晓岚. 淋巴细胞归巢在炎症性肠病中的作用及相关治疗靶点[J]. 临床荟萃, 2025, 40(5): 468-472.
[3]	柳玮娜, 柴国静. 血脂代谢与肺癌的相关性研究进展[J]. 临床荟萃, 2025, 40(11): 1031-1034.
[4]	赵金匣, 康慧慧, 张垚, 付生军, 孙鹏飞. 胃癌患者根治性切除术前血脂水平与预后的相关性[J]. 临床荟萃, 2024, 39(10): 889-895.
[5]	刘静, 刘连培, 张蒙蒙, 柴琳琳, 李容, 朱黎英. 胃底腺型胃癌1例并文献复习[J]. 临床荟萃, 2024, 39(10): 929-934.
[6]	赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29.
[7]	吕畅, 周利明. TNF-α-308基因多态性与胃癌易感相关性的meta分析[J]. 临床荟萃, 2023, 38(9): 779-787.
[8]	王英南, 赵琦, 白海威, 武丹娜, 魏金梅, 李省江, 李锐凌, 张瑞星. 胃癌合并脑梗死的临床特点及危险因素分析[J]. 临床荟萃, 2023, 38(5): 417-422.
[9]	王军宏, 高振华, 章荣龙, 姬浩民, 赵信科, 达明绪. 1980-2021年胃癌诊断文献相关质量分析——基于Web of Science 数据库的文献计量学分析[J]. 临床荟萃, 2023, 38(12): 1117-1124.
[10]	黄小敏, 赵旭辉, 达德转, 马桃梅, 李红玲. EB病毒感染和程序性死亡受体配体1表达在晚期胃癌免疫靶向治疗中的研究进展[J]. 临床荟萃, 2023, 38(11): 1048-1052.
[11]	王壮壮, 刘彦廷, 田春雷, 任欢, 艾文兵. 长链非编码RNA在胶质瘤中的研究进展[J]. 临床荟萃, 2023, 38(11): 1053-1056.
[12]	陶嘉楠, 田王钊, 安琪, 王学红, 张盛祺, 刘吉. SLP-2在胃癌中的表达及临床意义的Meta分析[J]. 临床荟萃, 2022, 37(4): 299-304.
[13]	晋颖, 汪湃, 冯世兵. 幽门螺杆菌及胃蛋白酶原、胃泌素17水平在胃癌前病变诊断中的应用价值[J]. 临床荟萃, 2021, 36(3): 233-237.
[14]	芦迅达, 冯志杰, 纪晨光, 尹凯歌, 刘丽. 早期胃癌内镜黏膜下剥离术后出血的危险因素分析[J]. 临床荟萃, 2021, 36(12): 1087-1091.
[15]	卢文艺, 赵明峰. 急性淋巴细胞白血病的规范治疗[J]. 临床荟萃, 2021, 36(10): 874-879.